A new study—published this week in Science Advances—uncovered a previously unknown genetic process that could inform the development of novel treatment options for glioblastoma.
The findings from the 2022 National Youth Tobacco Survey on e-cigarette use among U.S. youth, published by FDA and CDC in Morbidity & Mortality Weekly Report, show that youth use of e-cigarettes remains high, with 2.5 million (9.4%) of the nation’s middle and high school students reporting current e-cigarette use.
Researchers at Baylor College of Medicine found that a key genetic variant risk factor, PNPLA3, plays a synergistic role in increasing the risk for cirrhosis, liver cancer, and liver-related death when combined with alcohol use and obesity.
A clinical trial led by clinicians at Georgetown Lombardi Comprehensive Cancer Center showed a remarkable 20% advantage in the two-year OS rate for people with advanced melanoma who first received immunotherapy (72% survival rate) versus those who initially got targeted therapies (52% survival rate). Progression-free survival, where the cancer is stable or improving, was also trending in favor of those who started on immunotherapy.
A new class of small molecule drugs, now in phase I clinical trials, is the first to target circadian clock proteins, which play a key role in the recurrence and spread of glioblastoma.
University of Minnesota Medical School researchers explored the possible biological mechanisms that could explain the association between being overweight or obese prior to pregnancy and the increased risk of acute lymphoblastic leukemia in children.
New findings by the ACS found cumulative economic losses from cigarette smoking topped $891 billion in 2020, or 4.3% of the U.S. Gross Domestic Product. The economic loss significantly outpaced the cigarette industry’s $92 billion revenue by nearly a ten-to-one ratio. The study was published today in the journal The Lancet Public Health.
From March through December 2020, more than 16,000 cancer deaths were due to complications of COVID-19 in the U.S., according to a new study led by researchers at the American Cancer Society.
Moffitt Cancer Center has conducted the first prospective study to investigate genomic biomarkers associated with aggressive disease in African American men with prostate cancer, a population with disparities in incidence and mortality.
Former smokers who stick to a healthy lifestyle have a lower risk of dying from all causes than those who don’t engage in healthy habits, according to a study by researchers at NCI. The reduced risk of dying was observed for specific causes, including cancer.
